Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioRegenxBRGX EV-to-FCF is 339.43 as of Jul. 19, 2026. The stock has 5 warning signs investors should review. Among 404 Healthcare Providers & Services companies, BioRegenx ranks worse than 96.29% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioRegenx's Enterprise Value is $9.50 Mil.
BioRegenx's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $0.03 Mil. Therefore, BioRegenx's EV-to-FCF for today is 339.43.
The historical rank and industry rank for BioRegenx's EV-to-FCF or its related term are showing as below:
BRGX'
s EV-to-FCF Range Over the Past 10 Years
Min: -19397.69 Med: -24.71 Max: 476.88
Current: 339.43
During the past 12 years, the highest EV-to-FCF of BioRegenx was 476.88. The lowest was -19397.69. And the median was -24.71.
BRGX's EV-to-FCF is ranked worse than 96.29% of 404
companies
in the Healthcare Providers & Services industry
Industry Median: 18.215
vs BRGX: 339.43
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioRegenx's share price for today is $0.0076.
BioRegenx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioRegenx EV-to-FCF Related Terms
BioRegenx EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BioRegenx's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, BioRegenx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRegenx EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioRegenx's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BioRegenx's EV-to-FCF falls into.
BioRegenx's current Enterprise Value is $9.50 Mil.
BioRegenx's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRegenx (BRGX) has a EV-to-FCF of 339.43 as of Jul. 19, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioRegenx and its competitors. According to the industry distribution chart, BioRegenx ranks #389 out of 404 companies in the Healthcare Providers & Services industry, placing it in the top 96.3%.
Is BioRegenx's EV-to-FCF too high?
BioRegenx's current EV-to-FCF is 339.43. The Healthcare Providers & Services industry median EV-to-FCF is 18.22. BioRegenx's value of 339.43 is 1763.5% above this industry median. Based on the distribution chart, BioRegenx ranks #389 out of 404 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does BioRegenx's EV-to-FCF compare to VYND and ACON?
According to the Healthcare Providers & Services industry distribution chart, BioRegenx ranks #389 out of 404 companies for EV-to-FCF. This places BioRegenx in the lower half of its industry. The industry median EV-to-FCF is 18.22. BioRegenx's value of 339.43 is 1763.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.22, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRegenx's current EV-to-FCF of 339.43 is 1763.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioRegenx and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRegenx's current EV-to-FCF is 339.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRegenx stock overvalued right now?
Based on GuruFocus' analysis, BioRegenx (BRGX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 24% below its estimated fair value. The current EV-to-FCF is 339.43 and 1763.5% above the Healthcare Providers & Services industry median of 18.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BioRegenx (BRGX), the current EV-to-FCF is 339.43 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioRegenx Inc develops and manufactures medical test equipment and high-quality, science-based nutritional products. The Company distributes wellness devices. The products are sold nationally through a direct selling channel to health professionals and research organizations. The company operates and manages its business as one reportable and operating segment as a medical testing, diagnostic and nutraceutical company. It focuses on commercialization of its patented technologies in its field.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRGX has been successfully added to your 
